There is no market for new antibiotics: this allows an open approach to research and development

Klug, Dana M.; Idiris, Fahima I. M.; Blaskovich, Mark A. T.; Delft, Frank von; Dowson, Christopher G.; Kirchhelle, Claas; Roberts, Adam P.; Singer, Andrew C.; Todd, Matthew H.

doi:10.12688/wellcomeopenres.16847.1

Cited by 40 publications

(30 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UTI treatment may soon pose a challenge, as the situation is made worse by the lack of new antimicrobials. Recently, only three major pharmaceutical companies have been conducting research on developing new antibiotics [ 38 , 112 , 113 ].…”

Section: Obstacles In Uti Treatmentmentioning

confidence: 99%

Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic Escherichia coli—An Update

Rozwadowski

Gawel

2022

Genes

View full text Add to dashboard Cite

The rapid emergence of multidrug-resistant (MDR) bacteria indisputably constitutes a major global health problem. Pathogenic Escherichia coli are listed among the most critical group of bacteria that require fast development of new antibiotics and innovative treatment strategies. Among harmful extraintestinal Enterobacteriaceae strains, uropathogenic E. coli (UPEC) pose a significant health threat. UPEC are considered the major causative factor of urinary tract infection (UTI), the second-most commonly diagnosed infectious disease in humans worldwide. UTI treatment places a substantial financial burden on healthcare systems. Most importantly, the misuse of antibiotics during treatment has caused selection of strains with the ability to acquire MDR via miscellaneous mechanisms resulting in gaining resistance against many commonly prescribed antibiotics like ampicillin, gentamicin, cotrimoxazole and quinolones. Mobile genetic elements (MGEs) such as transposons, integrons and conjugative plasmids are the major drivers in spreading resistance genes in UPEC. The co-occurrence of various bacterial evasion strategies involving MGEs and the SOS stress response system requires further research and can potentially lead to the discovery of new, much-awaited therapeutic targets. Here, we analyzed and summarized recent discoveries regarding the role, mechanisms, and perspectives of MDR in the pathogenicity of UPEC.

show abstract

Section: Obstacles In Uti Treatmentmentioning

confidence: 99%

Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic Escherichia coli—An Update

Rozwadowski

Gawel

2022

Genes

View full text Add to dashboard Cite

show abstract

“…The problem of AMR is further complicated by a faltering research and development pipeline with only a few new drugs on the horizon. The latter is due to many factors, which are mainly related to pharmacoeconomics and the challenges, financial and otherwise, associated with discovering and bringing new antimicrobials to the market (32). For example, the cost of developing an antibiotic can be around 33-fold higher than the yearly revenue generated from the respective drug sales (33).…”

Section: Antimicrobial Resistance In Brief: a Global Public Health Th...mentioning

confidence: 99%

Catch-22: War, Refugees, COVID-19, and the Scourge of Antimicrobial Resistance

Osman

Cummings²,

Omari³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Wars have hidden repercussions beyond the immediate losses of life, well-being, and prosperity. Those that flee wars and seek refuge in safer locations are not immune to the tragic impacts. Of particular concern is the susceptibility of the refugee populations to infectious diseases and antimicrobial-resistant pathogens. This poses a detrimental risk to these disenfranchised populations, who often have limited access to medical care, sanitation, and nutritious and safe food. Furthermore, antimicrobial-resistant pathogens in refugees can be both transmitted to and acquired from their hosting communities. The latter is particularly problematic when the host countries suffer from serious challenges such as limited resources, pollution, and widespread antimicrobial resistance (AMR). Here, we discuss AMR in refugees of the ongoing Syrian war, a conflict that resulted in the largest population displacement in recent history. We argue that Syrian refugees and their hosting communities are at an elevated risk of complicated and life-threatening AMR infections. We also call on the international community to address this grievous problem that threatens the disenfranchised refugee populations and can spill over across geographic borders to affect multiple countries.

show abstract

“…Hospital strains and those associated with foodborne diseases pose a risk due to the extensive use and misuse of antibiotics for human health and livestock [ 5 , 6 , 7 ]. Moreover, new antimicrobials that block drug-resistant pathogens are not being developed quickly enough [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Current Landscape of Methods to Evaluate Antimicrobial Activity of Natural Extracts

et al. 2023

View full text Add to dashboard Cite

Natural extracts have been and continue to be used to treat a wide range of medical conditions, from infectious diseases to cancer, based on their convenience and therapeutic potential. Natural products derived from microbes, plants, and animals offer a broad variety of molecules and chemical compounds. Natural products are not only one of the most important sources for innovative drug development for animal and human health, but they are also an inspiration for synthetic biology and chemistry scientists towards the discovery of new bioactive compounds and pharmaceuticals. This is particularly relevant in the current context, where antimicrobial resistance has risen as a global health problem. Thus, efforts are being directed toward studying natural compounds’ chemical composition and bioactive potential to generate drugs with better efficacy and lower toxicity than existing molecules. Currently, a wide range of methodologies are used to analyze the in vitro activity of natural extracts to determine their suitability as antimicrobial agents. Despite traditional technologies being the most employed, technological advances have contributed to the implementation of methods able to circumvent issues related to analysis capacity, time, sensitivity, and reproducibility. This review produces an updated analysis of the conventional and current methods to evaluate the antimicrobial activity of natural compounds.

show abstract

There is no market for new antibiotics: this allows an open approach to research and development

Cited by 40 publications

References 52 publications

Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic Escherichia coli—An Update

Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic Escherichia coli—An Update

Catch-22: War, Refugees, COVID-19, and the Scourge of Antimicrobial Resistance

Current Landscape of Methods to Evaluate Antimicrobial Activity of Natural Extracts

Contact Info

Product

Resources

About